# The University of Kansas Cancer Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/the-university-of-kansas-cancer-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 66.7 |
| Citations | 284,323 |
| City | Kansas City |
| Country | US |
| Description | The University of Kansas Cancer Center is a research organisation in Kansas City, US. OpenAlex records 3,692 works and 284,323 citations for it. 699 researchers list it as their most recent affiliation. |
| Homepage | https://www.kucancercenter.org |
| OpenAlex ID | https://openalex.org/I4210097601 |
| Researchers | 699 |
| ROR ID | https://ror.org/00cj35179 |
| Type | facility |
| Works | 3,692 |

## University papers

- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
- [Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/genetic-familial-high-risk-assessment-breast-ovarian-and-pancreatic-version-2/)
- [A Population-Based Study of Genes Previously Implicated in Breast Cancer](https://scholariq.org/papers/a-population-based-study-of-genes-previously-implicated-in-breast-cancer/)
- [NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017](https://scholariq.org/papers/nccn-guidelines-insights-genetic-familial-high-risk-assessment-breast-and/)
- [Genetic/Familial High-Risk Assessment: Breast and Ovarian](https://scholariq.org/papers/genetic-familial-high-risk-assessment-breast-and-ovarian/)
- [NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020](https://scholariq.org/papers/nccn-guidelines-insights-genetic-familial-high-risk-assessment-breast-ovarian/)
- [Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer](https://scholariq.org/papers/personalized-circulating-tumor-dna-analysis-to-detect-residual-disease-after/)
- [Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores](https://scholariq.org/papers/prediction-of-breast-and-prostate-cancer-risks-in-male-i-brca1-i-and-i-brca2-i/)

## University top topics

Showing 8 of 25.

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Myeloproliferative Neoplasms: Diagnosis and Treatment](https://scholariq.org/topics/myeloproliferative-neoplasms-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.